Loading company…
Ocythera develops small molecule therapies for rare bone disorders.
Founded in 2021 and based in Montreal, Ocythera develops therapies for Hereditary Multiple Osteochondromas and Fibrodysplasia Ossificans Progressiva. Its research focuses on small molecule inhibitors that target enzymes involved in bone disease. In January 2026, the company raised an undisclosed amount of seed funding from adMare Bioinnovations and Investment Quebec to support research and development.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in